Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Intranet
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

New Indication Alert: MSD’s Keytruda® (pembrolizumab) Approved in Canada for New Gastric Cancer Indication

Apr 19, 2024

On 19 April 2024, Merck (known as MSD outside Canada and the US) announced that Health Canada has approved Keytruda® (pembrolizumab) as a 1st line treatment for locally advanced unresectable or metastatic HER2 negative gastric cancer or gastroesophageal junction adenocarcinoma in combination with fluoropyrimidine and platinum-based chemotherapy.

Keytruda® was approved for the same indication in the US in November 2023 and in Korea in March 2024, while a positive CHMP recommendation was received in Europe in October 2023.